en · de · es · fr · pt
cardarine-notes.peptides1126.com › Data › Mechanism And Detection — Research Overview

Mechanism And Detection — Research Overview

By Editorial Desk · published 2026-07-26 · last reviewed 2026-08-01 · Data

A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Cardarine at a glance

PropertyValueNotes
Molecular targetPPAR delta (NR1C2)Ligand-activated nuclear receptor.
Primary tissues studiedSkeletal muscle, liver, adiposeEffects on fatty acid oxidation and energy use.
Typical detection matrixUrineUsed in anti-doping analysis.
Common analytical methodLC-MS/MSDetects parent compound and metabolites.
Sport regulatory classProhibited at all timesListed as a metabolic modulator by WADA.

Background and Research Context

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

Related pages on this site

Background and Regulatory History

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

Mechanism and Laboratory Detection

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.

Reference notes

=== Extraction === Lactobacillic acid can be isolated from the lipids of bacteria, as used by the working group during the discovery. First, hydrolysis (saponification) of the phospholipids or triglycerides is carried out, releasing the fatty acid bound as an ester. Since other fatty acids are present in addition to lactobacillic acid, separation is then carried out using urea extraction crystallization or column chromatography. The fractional crystallization process can also be used.

Vincent Marks (10 June 1930 – 6 November 2023) was an English pathologist and clinical biochemist known for his works on studying insulin and hypoglycemia. His contributions to medical science include simplifying low blood glucose testing, introducing insulin radioimmunoassay, and advancing diabetes research. Marks played an important role in high-profile medico-legal cases, notably providing expert testimony that helped acquit Danish-born British socialite Claus von Bülow in 1985, a case that was the basis of the Oscar-winning movie Reversal of Fortune (1990). Marks was also a nutritionist who studied intestinal hormones and coined the term "muesli belt malnutrition", referring to parents feeding their children what is considered extremely healthy foods, but, in the process depriving them of essential fats.

Zinc deficiency may lead to loss of appetite. The use of zinc in the treatment of anorexia has been advocated since 1979. At least 15 clinical trials have shown that zinc improved weight gain in anorexia. A 1994 trial showed that zinc doubled the rate of body mass increase in the treatment of anorexia nervosa. Deficiency of other nutrients such as tyrosine, tryptophan and thiamine could contribute to this phenomenon of "malnutrition-induced malnutrition". A meta-analysis of 33 prospective intervention trials regarding zinc supplementation and its effects on the growth of children in many countries showed that zinc supplementation alone had a statistically significant effect on linear growth and body weight gain, indicating that other deficiencies that may have been present were not responsible for growth retardation.

Anti-Ro and anti-La antibodies, also known as SS-A and SS-B, respectively, are commonly found in primary Sjögren's syndrome, an autoimmune disorder that affects the exocrine glands. The presence of both antibodies is found in 30–60% of Sjögren's syndrome, anti-Ro antibodies alone are found in 50–70% of Sjögren's syndrome and 30% of SLE with cutaneous involvement, and anti-La antibodies are rarely found in isolation. Anti-La antibodies are also found in SLE; however, Sjögren's syndrome is normally also present. Anti-Ro antibodies are also found less frequently in other disorders including autoimmune liver diseases, coeliac disease, autoimmune rheumatic diseases, cardiac neonatal lupus erythematosus and polymyositis. During pregnancy, anti-Ro antibodies can cross the placenta and cause heart block and neonatal lupus in babies. In Sjögren's syndrome, anti-Ro and anti-La antibodies correlate with early onset, increased disease duration, parotid gland enlargement, disease outside the glands and infiltration of glands by lymphocytes. Anti-Ro antibodies are specific to components of the Ro-RNP complex, comprising 45kDa, 52kDa, 54kDa and 60kDa proteins and RNA. The 60kDa DNA/RNA binding protein and 52kDa T-cell regulatory protein are the best characterised antigens of anti-Ro antibodies. Collectively, these proteins are part of a ribonucleoprotein (RNP) complex that associate with the human Y RNAs, hY1-hY5. The La antigen is a 48kDa transcription termination factor of RNA polymerase III, which associates with the Ro-RNP complex.

Research is being carried out on the use of stem cells for the generation of an artificial liver. Scientific and medical works about liver regeneration often refer to the Greek Titan Prometheus who was chained to a rock in the Caucasus where, each day, his liver was devoured by an eagle, only to grow back each night. The myth suggests the ancient Greeks may have known about the liver's remarkable capacity for self-repair.

Sources: en.wikipedia.org

Notes from published material

An injection port is a medical device used for the administration of insulin or other physician-approved medicine into the subcutaneous tissue (the tissue layer just below the skin). The device is similar to infusion sets used by insulin pumps, except it is configured to receive a syringe instead of a tubing system. An injection port is usually a disposable device applied by the patient and worn for period of 3–5 days. When giving shots via an injection port, the needle stays above the surface of the skin Medication is delivered via a short soft cannula. An injection port can be used in conjunction with multiple daily injections of insulin by people with diabetes. It can also be used for the subcutaneous administration of any other physician prescribed medication.

In March 2003, 2–325 of the 2nd BCT was attached to the 75th Ranger Regiment as part of a special operations task force to conduct a parachute assault to seize Saddam International Airport, part of Operation Iraqi Freedom. On 21 March 2003, Company D, 2-325 crossed the Saudi Arabia–Iraq border as part of Task Force Hunter to escort HIMARS artillery systems to destroy Iraqi artillery batteries in the western Iraqi desert. Upon cancellation of the parachute assault to seize the airport, the battalion returned to its parent 2nd Brigade at Talil Airfield near An Nasariyah, Iraq. The 2nd Brigade then conducted operations in Samawah, Fallujah, and Baghdad. The brigade returned to the United States by the end of February 2004. The early days of the 82nd Airborne's participation in the deployment were chronicled by embedded journalist Karl Zinsmeister in his 2003 book Boots on the Ground: A Month with the 82nd Airborne in the Battle for Iraq. In April 2003, according to Human Rights Watch, soldiers from a subordinate unit, the 1st battalion of the 325th Infantry, allegedly fired indiscriminately into a crowd of Iraqi civilians protesting their presence in the city of Fallujah, killing and wounding many civilians. The battalion suffered no casualties. The 3rd Brigade deployed to Iraq in the summer, redeploying to the US in spring 2004. The 1st Brigade deployed in January 2004. The last units of the division left by the end of April 2004. The 2nd Brigade deployed on 7 December 2004 to support the free elections and returned on Easter Sunday in 2005.

=== Other impacts === In 1985, Henry Waxman, an American politician, called for a U.S. government inquiry into the Bhopal disaster, which resulted in U.S. legislation regarding the accidental release of toxic chemicals in the United States.

A ribosome is a ribonucleoprotein particle made from complexes of ribosomal RNAs and proteins, arranged into two ribosomal subunits, one large and the other small. Ribosomes are complex molecular machines present in all cells both prokaryotic, and eukaryotic. The ribosomal subunits of prokaryotes and eukaryotes are quite similar. A ribosome is largely made up of specialized non-coding ribosomal RNA (rRNA) as well as dozens of distinct ribosomal proteins (the number varies slightly between species). The ribosomal proteins and rRNAs are arranged into two distinct ribosomal subunits one large and one small. The subunits fit together locking around a strand of mRNA, and work together to translate the mRNA into a polypeptide chain during protein synthesis.

Sources: en.wikipedia.org

Background from the literature

Committee on Energy and Commerce Subcommittee on Health Subcommittee on Communications & Technology Subcommittee on Commerce, Manufacturing and Trade Committee on Natural Resources Subcommittee on Water, Wildlife, and Fisheries Subcommittee on Energy & Mineral Resources

== Cancer == Grape seed extract has been incorrectly described as a cancer cure on social media websites. There is no clinical evidence that grape seed extract is effective to treat cancer. In 2017, the Food and Drug Administration listed grape seed extract as a fake cancer cure that consumers should avoid.

The side effect profile of bicalutamide in men and women differs from that of other antiandrogens and is considered favorable in comparison. Relative to GnRH analogues and the steroidal antiandrogen (SAA) cyproterone acetate (CPA), bicalutamide monotherapy has a much lower incidence and severity of hot flashes and sexual dysfunction. In addition, unlike GnRH analogues and CPA, bicalutamide monotherapy is not associated with decreased bone mineral density or osteoporosis. Conversely, bicalutamide monotherapy is associated with much higher rates of breast tenderness, gynecomastia, and feminization in men than GnRH analogues and CPA. However, gynecomastia with bicalutamide is rarely severe and discontinuation rates due to this side effect are fairly low. These differences in side effects between bicalutamide monotherapy, GnRH analogues, and CPA are attributed to the fact that whereas GnRH analogues and CPA suppress estrogen production, bicalutamide monotherapy does not lower estrogen levels and in fact actually increases them. Bicalutamide does not share the risk of neuropsychiatric side effects like fatigue as well as cardiovascular side effects like coagulation changes, blood clots, fluid retention, ischemic cardiomyopathy, and adverse serum lipid changes that CPA has been associated with. It has a much lower risk of hepatotoxicity than flutamide and CPA and of interstitial pneumonitis than nilutamide. The drug also does not share the unique risks of diarrhea with flutamide and nausea, vomiting, visual disturbances, and alcohol intolerance with nilutamide.

==== Department of Commerce Military End Use/User Rule ==== The U.S. government also enforces stricter restrictions on a more expansive definition of defense items, including the export of any U.S.-origin item that "supports or contributes" to the operation, installation, maintenance, repair, overhaul, refurbishing, development, or production of military items to specified countries. The same countries are also subject to additional license requirements for certain exports to the targeted countries' "military end users," defined as their national armed services, national police, national intelligence services, and anyone whose activities "support or contribute to military end uses."

=== EGFR side effects === Epidermal growth factor receptor (EGFR) inhibitors are medications used in cancer treatment. These medications commonly cause skin and nail problems, including rashes, dry skin and paronychia. Preventive intensive moisturizing with emollient ointments several times, avoidance of water-based creams and water soaks (although in certain circumstances white vinegar or potassium permanganate soaks may help), protection the skin from excessive exposure to sunshine, and soap substitutes which are less dehydrating for the skin than normal soaps, as well as shampoos that reduce the risk of scalp folliculitis, are recommended. Treatment measures with topical antibiotic medication can be helpful.

Sources: en.wikipedia.org

Frequently asked questions

How does cardarine work in the body?

It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.

Did human trials show benefits?

Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.

Can anti-doping tests detect cardarine?

Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Network